Market News

Dallas-based Senderra Rx achieves perfect net promoter score.
The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017.
Excelera has announced the appointment of Lorrie A. Carr as its new CEO. Ms. Carr succeeds Jim Fox who retired effective April 2.
New FDA-approved therapy offers more options to patients with advanced type of skin cancer.
Company’s Clinical Expertise, Positive Patient Outcomes Garners Access to Limited Drug Distribution.
Collaboration Brings Technology Advancements to Specialty Pharmacy Marketplace to Deliver Better Outcomes, Quality, Efficiency and Cost Management.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$